Raloxifene Hydrochloride
RALOXIFENE HCL · (6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)Methanone hydrochloride · CS-127 · ly156758 · KEOXIFENE · LY 139481 · AKOS 92138 · RALOXFENE HCL
Identifikatoren & physikalische Daten
| CAS No. | 82640-04-8 |
|---|---|
| Summenformel | C28H28ClNO4S |
| Durchschnittliche Molmasse | 510 g/mol |
| Monoisotopische Masse | 509,14275706 g/mol |
| SMILES | Cl.O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12 |
| InChIKey | BKXVVCILCIUCLG-UHFFFAOYSA-N |
| PubChem CID | 54900 |
| ChEMBL | CHEMBL1116 |
| ChEBI | CHEBI:50740 |
| EC No. | 639-789-7 |
| DTXSID | DTXSID1034181 |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 98,2 |
|---|---|
| H-Brücken-Donoren | 3 |
| H-Brücken-Akzeptoren | 6 |
| Frei drehbare Bindungen | 7 |
| Schwere Atome | 35 |
| Formalladung | 0 |
| Komplexität | 655 |
| Human Drugs | FDA approved drugs -> Active ingredientEMA approved medicines: Human medicine |
| Collision Cross Section | 213.4 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| Schmelzpunkt | 250-253°C |
| Lagerbedingungen | 2-8°C |
| Löslichkeit | DMSO: 28 mg/mL, soluble |
| Aggregatzustand | solid |
| Farbe | light yellow |
| Merck | 14,8098 |
| BCS Class | 2 |
| Hauptanwendungen | pharmaceutical (small molecule) |
| InChI | 1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2 |
| InChIKey | BKXVVCILCIUCLG-UHFFFAOYSA-N |
| SMILES | C1(C(=O)C2C=CC(OCCN3CCCCC3)=CC=2)C2C=CC(O)=CC=2SC=1C1C=CC(O)=CC=1.Cl |
| CAS Datenbank | 82640-04-8(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH351 (82.4%): Suspected of causing cancer [Warning Carcinogenicity]P203, P273, P280, P318, P391, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 68 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Carc. 2 (82.4%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Raloxifene hydrochloridevLess-DILI-concernNo matchDOI:10.1016/j.drudis.2016.02.015 |
| Wassergefährdungsklasse (WGK) | 3 |
| Zollcode | 2934990002 |
| RTECS-Nr. | PC4956925 |
| R-Sätze (R) | 36/37/38 |
| Gefahrensymbole | Xi |
| Sicherheitshinweise (S) | 22-24/25 |
| Lagerklasse | 11 - Combustible Solids |
| Gefahrenklasse | Carc. 2Repr. 2 |
Anwendungen & Verwendung
Beschreibung
Raloxifene was launched as Evista in the US for the prevention of postmenopausal osteoporosis. It is noteworthy that this molecule was formerly under development as keoxifene for breast cancer and prostatic hypertrophy. Raloxifene can be prepared by acylation of 6-methoxy-2-(4-methoxyphenyl) benzothiophene followed by simultaneous demethylation of both methoxy groups. Raloxifen is a selective estrogen receptor modulator, exerting antiestrogenic action on certain tissues (breast) and also estrogenic action on bone metabolism or serum lipids. In normal early postmenopausal women, 200 mg daily produced a trend towards suppression of estrogen effects. Raloxifen impeded bone loss in osteoporosis. A two-year study in postmenopausal women with an increased risk for osteoporosis showed that Raloxifen markedly prevented non-traumatic vertebral fractures. Results of several clinical studies demonstrated that Raloxifen appreciably reduced the risk of developing breast cancer. Moreover, it had favourable effect on lipid profiles without having the potential side-effects of estrogen-based therapies. Several extensions for different uses of this molecule are planned, for example growth disorder, obesity, colon tumor and skin atrophy. No serious drug-related events have been reported in the limited number of clinical trials.
Verwenden
Raloxifene hydrochloride can be used as a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.